Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-07-01

FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)

View source ↗

Summary

FDA approved a supplemental application for alogliptin, a diabetes medication, submitted by Padagis Israel Pharmaceuticals Ltd, reflecting changes to the labeli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alogliptin (alogliptin)

Snippet

SUPPL AP for ALOGLIPTIN (ALOGLIPTIN)